Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22049829 | 0.83 | CLK2 (0.54) | CLK2DYRK1ASTING1NAMPTTRPV1 | |
| SCHEMBL22050192 | 0.83 | CLK2 (0.54) | CLK2DYRK1ASTING1NAMPTTRPV1 | |
| SCHEMBL22049735 | 0.83 | DYRK1A (0.49) | CLK2DYRK1ABRAFSTING1IGF1R | |
| SCHEMBL22049655 | 0.83 | CLK2 (0.54) | CLK2DYRK1ASTING1NAMPTTRPV1 | |
| SCHEMBL22050223 | 0.80 | TRPV1 (0.58) | BRAFSTING1TRPV1P2RY1RIPK1 | |
| SCHEMBL22049393 | 0.77 | RAB9A (0.56) | CLK2DYRK1ABRAFSTING1TRPV1 | |
| SCHEMBL22049594 | 0.77 | STING1 (0.51) | DYRK1ABRAFSTING1AAK1RAB9A | |
| SCHEMBL22050711 | 0.76 | CAMKK1 (0.42) | BRAFSTING1NAMPT | |
| SCHEMBL22236081 | 0.75 | CLK2 (0.68) | CLK2DYRK1ANAMPTRAB9A | |
| SCHEMBL22828671 | 0.72 | CLK2 (0.49) | CLK2DYRK1AIGF1RTRPV1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CLK2 1343/4885DYRK1A 4056/4885BRAF 369/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | CLK2 867/4885DYRK1A 2647/4885BRAF 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.